

Elgin St. Thomas Site

Administrative Office
1230 Talbot Street
St. Thomas, ON
N5P 1G9

Woodstock Site

410 Buller Street
Woodstock, ON
N4S 4N2



October 15, 2020

From the Office of Dr. Joyce Lock, Medical Officer of Health, Southwestern Public Health

Update to the Ontario Publicly Funded Shingles (Herpes Zoster) Immunization Program – TRANSITION TO SHINGRIX® from ZOSTAVAX II®

Since September 2016, Ontario has offered seniors aged 65 – 70 years of age a one-time publicly funded dose of vaccine to protect against the Herpes Zoster (HZ) through the publicly funded immunization program. The product used since 2016 has been Zostavax II®.

Current evidence and expert opinion indicate that Shingrix® is more effective for preventing HZ infection and related complications. Shingrix's efficacy is above 90% for HZ incidence and 88-91% for the prevention of post-herpetic neuralgia. It also demonstrates slower waning immunity.

Shingrix is a safe vaccine with rarely reported serious adverse events.

Starting in early November, the Ontario publicly funded immunization program will transition from the Zostavax II vaccine to the Shingrix vaccine.

- **YOUR CURRENT SUPPLY OF ZOSTAVAX II IS DUE TO EXPIRE OCTOBER 21, 2020.**

Shingrix is a recombinant series with the 2nd dose given 2-6 months after the first dose.

Ontario seniors aged 65 – 70 years of age (from the 65th birthday to the day prior to the 71st birthday) are eligible for the 2-dose Shingrix series provided they HAVE NOT received publicly funded Zostavax II.

- Note: As a result of COVID-19, seniors born in 1949 or 1950 (70-year old turning 71 in 2020 or 2021 calendar year) who missed receiving publicly funded Zostavax II are eligible to receive Shingrix vaccine and complete their 2-dose series by December 31st, 2021.

Seniors aged 65-70 years of age who purchased the Zostavax II vaccine are eligible to receive a publicly funded Shingrix vaccine series.

ACTIONS:

- Refer to the attached Shingrix Patient Information Sheet and the Health Care Provider Q&A documents.
- Order Shingrix vaccine starting October 19, 2020 using the updated routine order form on our website or in-office tear-off pads.
- Complete a SWPH Vaccine return form (<https://www.swpublichealth.ca/professionals/health-care->

- [providers/vaccine-ordering-fridge-inspection](#)) and return all unused doses of Zostavax II to SWPH.
- Educate patients regarding the **2-dose schedule** for Shingrix to promote adherence.
 - Educate patients regarding short-term reactogenicity of Shingrix vaccine to promote adherence to 2-dose schedule. Local reactions may occur and are common after first dose.

Dr. Joyce Lock
Medical Officer of Health
Southwestern Public Health
jlock@swpublichealth.ca
1-800-922-0096, ext.1255

Staff contact for information:
Jaime Fletcher
Program Manager, Immunization
jfletcher@swpublichealth.ca
1-800-922-0096, ext. 1234